Dr Reddy’s Pins Hopes On Complex Drugs Pipeline Amid Weak Q3

Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a 29% drop in quarterly net profit, hit by price erosion in its main US market.

Pharma pills
DR REDDY'S IS BETTING ON COMPLEX DRUGS TO POWER ITS RECOVERY

Dr. Reddy's Laboratories Ltd.’s quarterly results are emblematic of the malaise afflicting India’s flagship generic drug sector. The industry has been pummeled by double-digit price erosion in its main US market with drug distributors consolidating their buying power and the US FDA awarding approvals at a record rate. The US contributes nearly half of Dr Reddy’s total revenue.

“We anticipate the market dynamics will remain challenging in the near-term,” Dr Reddy’s chief operating officer Abhijit Mukherjee told analysts...

Welcome to Scrip

Create an account to read this article

More from Business

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

More from Scrip

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By 

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.